serum levels of ACTH or cortisol; in fact, resultant elevated levels of ACTH may ultimately limit its utility given the inability to distinguish whether such an elevation is due to the medication alone or an enlarging adenoma, requiring frequent pituitary imaging. Furthermore, in addition to possible resultant skin hyperpigmentation due to excess ACTH, endogenous cortisol elevations may ultimately overwhelm the receptor antagonism. The authors of one report used the drug as a last resort in an extremely ill patient with an ACTH-secreting macroadenoma and profound metabolic disturbances, psychosis, and cardiomyopathy, obtaining successful resolution of these symptoms (including significant reversal of heart failure). 3 Notably, however, spironolactone was needed to manage resultant hypokalemia, attributed to the unhindered mineralocorticoid activity of excess cortisol.
Overall, the most well-studied and efficacious pharmacological therapies include the adrenal enzyme inhibitors ketoconazole, aminoglutethimide, metyrapone, and etomidate (intravenously administered) as well as the adrenolytic agent mitotane, which additionally has inhibitory effects on several adrenal enzymes. Figure 1 provides a summary of the effects of these medications on adrenal steroid synthesis. Most often, therapy is initiated with ketoconazole. If cortisol levels are not adequately controlled, metyrapone and/or aminoglutethimide can be added to the medication regimen as needed (Fig. 2) . Such combinations of these medications are quite common and allow usage of potential synergistic effects among them while limiting side effects that would occur if exceedingly high doses of one medication were used. One drawback to adrenal enzyme inhibitors is the need to increase doses with time because the relative decrease in cortisol they cause can stimulate further ACTH secretion. Additionally, the side effects of these medications (Table 1 ) may ultimately limit their use.
At any juncture, an alternative for patients becomes bilateral laparoscopic adrenalectomy. 11 The authors of a recent publication showed that during a 3-month to 10-year follow-up period, 79.4% of patients had undetectable serum cortisol levels whereas the procedure itself was asso-B. A. Gross et al. ciated with a 0% morality rate and 10.3% morbidity rate. 30 Such patients should, however, be monitored closely for the development of Nelson syndrome. In the aforementioned study the investigators reported that 25.7% of patients had serum ACTH levels greater than 300 pg/ml, 8.6% had magnetic resonance imaging evidence of tumor growth, and 11.1% had clinically significant hyperpigmentation.
Ketoconazole Therapy
Ketoconazole, the initial drug of choice, is administered at initial doses of 200 mg (two to three times daily) with dose adjustments based on 24-hour urine free cortisol levels. Maintenance doses are often at 400 mg (two to three times daily). Its fast onset of action allows monitoring of serum cortisol within as little as 1 day of use to observe its efficacy and adjust its dosage. Although its strongest effects are on 17,20-lyase, 32 it additionally blocks adrenal steroid synthesis by preventing cholesterol side chain cleavage and 17␣-hydroxylase. 8, 14 Though controversial, it is generally accepted that it does not in fact block human 11␣-hydroxylase. 14 The authors of a metaanalysis of eight trials involving a range of 400 to 1200 mg of ketoconazole daily in patients with Cushing disease revealed an average remission rate of 70% (range 25-93%). 7 Across these studies the most common side effect was hepatotoxicity, observed at an overall rate of 12%. 7 Notably, authors of the study with the most cases (34 patients) and longest follow-up period (up to 3 years) reported 26 patients (76%) with normalized cortisol levels when they used daily doses of ketoconazole ranging from 400 to 800 mg. 29 This percentage was further increased to 93% (26 of 28) when patients who initially discontinued use of the medication were excluded.
Liver function should be closely monitored during ketoconazole use considering the drug's ability to cause idiosyncratic reversible hepatic dysfunction and elevation of aminotransferase levels. These are likely to be dose-dependent effects because the prevalence of overt hepatitis decreases in patients treated with lower doses of the drug for onychomycosis (2.9% prevalence for a daily dosage of 200 mg).
1 Therapy should be promptly ceased in patients with hepatitis, but in patients with asymptomatic anicteric aminotransferase elevations, the decision is at the physician's discretion, although the only investigators who have advocated continuing the drug were those using it at lower doses for onychomycosis. 1 In addition to hepatic side effects, nausea, vomiting, headache, and sedation may occur. Other noted side effects of this medication include decreased libido and impotence, probably owing to its inhibitory effects on 17␣-hydroxylase and 17,20-lyase, vital enzymes for the synthesis of androgens as shown in Fig. 1 . Teratogenicity contraindicates use of this medication in pregnant women. Significant medication interactions may occur due to ketoconazole's potent inhibitory effects on the cytochrome P450 enzymes, particularly CYP3A4, CYP2C9, and CYP1A2. The CYP3A4 substrates include most benzodiazepines aside from lorazepam; many calcium channel blockers such as nifedipine and verapamil; 3-hydroxy-3-methyl-glutarylCoA reductase inhibitors, aside from pravastatin and fluvastatin; and pimozide, generally contraindicating their use. The CYP2C9 substrates include fluoxetine, glipizide, losartan, montelukast, phenytoin, and warfarin. The CYP1A2 substrates include mirtazapine, ropinirole, and theophylline. Sildenafil, tadalafil, and vardenafil concentrations may also be increased. The CYP3A4 inducers such as aminoglutethimide, carbamazepine, and phenytoin may decrease ketoconazole levels, and as ketoconazole absorp-
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Medical management of Cushing disease tion depends on gastric acidity, histamine-2 recepter blockers and proton-pump inhibitors should be avoided.
Aside from side effects and medication interactions, an ultimate limitation of this medication used alone may be a resultant serum ACTH elevation that overwhelms the drug's inhibitory effects. Citing their own unpublished cases, the authors of the aforementioned metaanalysis found that mean serum ACTH levels rose by an average of 35% in patients in remission whereas they rose by an average of 80% in patients in whom there was no normalization of urinary cortisol levels. 7 This limitation can be addressed by using additional adrenal enzyme inhibitors.
Metyrapone Therapy
Metyrapone is often started at three daily doses of 250 mg, with titration up to a maximum of 6 g per day. It acts as an inhibitor of 11␣-hydroxylase. Unfortunately, the resultant relative decrease in cortisol may stimulate further ACTH secretion, stimulating adrenal androgen and mineralocorticoid production and leading to further hirsutism and hypertension from these respective compounds. These side effects are less commonly observed in association with mitotane, another 11␣-hydroxylase inhibitor, presumably due to its inhibitory effect on other enzymes involved in adrenal androgen and mineralocorticoid synthesis. Other common side effects of metyrapone include edema, nausea, and vomiting.
Despite increased ACTH secretion, the inhibitory effect of metyrapone overcomes the increased drive to produce cortisol and has shown efficacy over an extended period in case reports-one including a 13-year-old boy receiving a 2-g regimen of metyrapone for 4 years. All cushingoid features disappeared and the patient grew 23 cm. 5 In a larger study including 53 patients with Cushing disease, the authors reported effective short-term mean serum cortisol level control (Յ 400 nmol/L) in 75% of patients with effective long-term control in 83% of the 24 patients who were given metyrapone (mean 2250 mg/day, median 27 months) following pituitary irradiation. 31 Of note, however, the criterion for "cortisol control" in the latter study was a mean serum level less than 400 nmol/L. When the more accepted, stringent criterion of Orth and Liddle 21 is applied (280 nmol/L cutoff), only 19% of patients experienced an effective short-term response. Overall, Orth 20 concluded that metyrapone is only useful as adjunctive treatment for Cushing disease. Of note, metyrapone is not available in pharmacies but can be provided for compassionate use by contacting the manufacturer directly.
Aminoglutethimide Therapy
Aminoglutethimide, often used at a dose of 250 mg two to three times daily, prevents conversion of cholesterol to pregnenolone. 25 In an original study of 33 patients with Cushing disease receiving a 250-mg dosage of aminoglutethimide three times daily, the authors noted a clinical and biochemical remission rate of 42%, the latter defined as a 50% reduction in morning serum cortisol levels or a return to normal limits. 17 Unclear, however, was the duration of follow-up for these patients, and, in the authors' extended discussion of a representative case of aminoglutethimide therapy for Cushing disease, the patient ultimately required bilateral adrenalectomy for continued biochemical remission. 17 Indeed, it is generally accepted that aminoglutethimide is, overall, not efficacious as monotherapy because its effect is generally not strong enough to normalize urinary cortisol levels, likely owing to, in part, the ability of resultant elevated ACTH to overwhelm its effect. 7 Thus, it is now most often used as an adjunct to metyrapone, with one study showing efficacy up to 1 year when the drug was administered at 500 to 750 mg per day in conjunction with 2 g of metyrapone daily in four of six patients;
2 the other two patients discontinued the drug due to side effects. The primary side effect of this medication is a generalized, self-limited pruritic rash that is usually manageable with antihistamines without requiring drug cessation. In addition, nausea and somnolence may occur, particularly at higher doses. Other neurological side effects include dizziness and blurred vision. As the drug blocks thyroid hormone synthesis, hypothyroidism is a known, albeit more rare, side effect. 25 Cholestasis and bone marrow suppression are similarly rare side effects. In addition, aminoglutethimide is a strong inducer of several cytochrome P450 enzymes, including CYP1A2 and CYP3A4, underscoring potential medication interactions, including decreasing ketoconazole levels (see above for other substrates of these enzymes). Because this medication increases the metabolism of dexamethasone but not hydrocortisone, the latter is often used if steroid replacement is needed.
25,26

Mitotane Therapy
Mitotane is often started at 250 to 500 mg nightly with slow escalation of the dose to 4 to 12g/day. Mitotane inhibits 11␣-hydroxylase, 18-hydroxylase, 3␣-hydroxylase, hydroxysteroid dehydrogenase, and several cholesterol side chain cleavage enzymes. 10, 18 At doses greater than 4 g per day, it has adrenolytic action because its metabolite binds macromolecules in adrenal cortical cell mitochondria, leading to their destruction and cellular necrosis. This property underscores its primary use in patients with adrenocortical carcinoma.
In a study of 46 patients with Cushing disease receiving anywhere from 4 to 12 g of mitotane per day, remission occurred in 8 months in 38 cases (83%). 15 Unfortunately, however, in 60% of these patients relapse occurred after the drug was discontinued, leaving only one third of patients with long-term remission. In another study of 36 patients undergoing adjunctive radiotherapy (4000 rad) the authors observed clinical and biological remission in 29 patients (81%) with 17 (47%) ceasing to undergo long-term mito- 27 Four patients had no response, two had partial responses, and the other patient died of an invasive pituitary malignancy. Patients were initially started at 4 g of mitotane per day and the dose was tapered to a final dose of 500 mg twice weekly.
The efficacy of mitotane is monitored by examining morning serum cortisol levels. Once a decline is observed, prednisone or dexamethasone replacement therapy can begin as needed. Although the longer half-life of dexamethasone may make it seem to be a more attractive replacement therapy, its metabolism is increased by mitotane (as is the metabolism of fludrocortisone), requiring dose adjustments, whereas the metabolism of cortisol or prednisone has not been shown to be increased. 24 Of note, patients who undergo medical mitotane adrenalectomy are at risk of developing Nelson syndrome if they do not receive pituitary radiotherapy.
Unfortunately, side effects of this medication may limit its use and have essentially set it as second or third line after ketoconazole. In the aforementioned studies, one group documented hypercholesterolemia as a prevalent side effect 15 whereas another, which also used pituitary irradiation, documented anorexia, nausea, diarrhea, decreased memory, and gynecomastia. 27 Overall, the most commonly documented drug-related side effects are nausea and hypercholesterolemia. At higher doses of the drug, neurological side effects are common, including gait ataxia, vertigo, confusion, and difficulty with language expression. 18 Furthermore, the drug is contraindicated in pregnant women owing to teratogenicity. 13 
Etomidate Therapy
Etomidate, a commonly used short-acting intravenous anesthestic, is an exceedingly potent inhibitor of 11␣-hydroxylase as well as an inhibitor of 17␣-hydroxylase at a strength comparable to ketoconazole. 32 It essentially serves as an intravenous alternative to the aforementioned medications; however, given its sedative effects and availability in intravenous form alone, it is mainly used for acute control of hypercortisolemia. Most investigators to date have analyzed its use in hospitalized patients with neoplasms secreting ACTH. In one study in which the authors used it at a nonsedating dose of 0.3 mg/kg/hour, it normalized serum cortisol levels within 12 hours in six patients with Cushing disease. 6 
Conclusions
Although medical management of Cushing disease is generally not considered a first-line option, it has exhibited adequate success as a preoperative, radiosurgical adjunct, or even as a stand-alone measure. Attempts to control ACTH levels with neuromodulators have demonstrated only limited success, but the use of adrenal enzyme inhibitors has shown some promise to date. Given its tolerability and average efficacy of 70% (range 25-93%) in trials, 7 ketoconazole is often the initial pharmacological agent utilized. Subsequently, one may add metyrapone and/or aminoglutethimide for further control of cortisol levels. The adrenolytic agent mitotane is another alternative that is often used as a second or third choice owing to its side effects. Etomidate is a potent intravenous alternative for acute cortisol control.
